Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Erik Brecelj) .

1 - 10 / 24
First pagePrevious page123Next pageLast page
1.
Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer
Borut Štabuc, Aleksandra Markovič, Erik Brecelj, Samir Bešlija, Tomaž-Edvard Cizej, 1998, original scientific article

Abstract: Based on in viro studies that have demonstrated synergy between fluorouracil (5-FU) and leucovorin (LV) as well as between 5-FU and recombinant alpha-2a interferon (IFN) against colon cancer cell lines a phase II study was carried out to evaluate the toxicity and clinical activity of 5-FU modulated with LV and IFN in patients with metastatic colon cancer. Twenty-two chemotherapy naive patients with measurable metastases of colon cancer have been treated with daily doses of 5-FU 600 mg/m2 in 6-hr intravenous infusion, and of LV 20 mg/m2 intravenously and IFN 6 MU subcutaneously, for 5 days every 4 weeks. Median age was 60 years, median PS (ECOG) was 1 (range 0-2). Liver, soft tissue and lung metastases were found in 12, 5 and 8 patients, respectively. Nineteen patients had a single metastatic site, two double, whereas one had more than two metastatic sites. Patients had 2-9 (mean 5) cycles of treatment.Objective response was observed in 7 patients (32%), and stable disease in 7 patients (32%). Overall median survival was 12.5 months, and for responders 14.4 months. Responses were generally short and median time for progression was 5.5 months. The most frequent adverse reactions were flu-like syndrome (50%), nausea/vomiting (36%), diarhoea (13Č), stomatitis (27%) and leucopenia (13%). This regimen of 5-FU with LV and IFN administration does notappear to be superior to previously published shedules of 5-FU with IFN or 5-FU with LV.
Published in DiRROS: 19.01.2024; Views: 85; Downloads: 33
.pdf Full text (430,62 KB)

2.
Sodobno zdravljenje lokalno napredovalega in recidivnega raka danke
Erik Brecelj, 2022, published scientific conference contribution

Abstract: Zdravljenje lokalno napredovalega in recidivnega raka danke je zahtevno. Z uvedbo boljše diagnostike, novih načinov predoperativnega zdravljenja na eni strani in z bolj agresivno kirurško terapijo na drugi strani dosegamo več R0 resekcij, ki edine omogočajo potencialno ozdravitev. Še vedno pa so ti posegi za bolnike neredko mutilantni. Z ustreznimi tehnikami rekonstrukcije dosegamo večjo možnost resektabilnosti, hkrati pa so posledice kirurškega zdravljenja manjše. Pomembna pri vrnitvi bolnika v normalno življenje sta prehranska podpora in rehabilitacija. Tako kompleksno zdravljenje je možno samo v multidisciplinarnem timu.
Keywords: rak danke, kirurško zdravljenje, rak prebavil
Published in DiRROS: 13.01.2023; Views: 484; Downloads: 89
.pdf Full text (88,46 KB)

3.
4.
5.
Priročnik za bolnike z izločalno stomo
Andreja Klinc, Dragica Tomc, Sabina Medjedović, 2021, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: rak črevesja, rak sečil, stoma
Published in DiRROS: 14.07.2022; Views: 545; Downloads: 171
.pdf Full text (769,40 KB)

6.
Smernice za obravnavo bolnikov s skvamoznoceličnim karcinomom analnega kanala in kože perinealno (analnega roba)
2020, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: rak analnega kanala, rak analnega roba, bolniki, zdravljenje
Published in DiRROS: 18.03.2022; Views: 639; Downloads: 349
.pdf Full text (407,06 KB)
This document has many files! More...

7.
Priporočila za obravnavo bolnikov z rakom debelega črevesa in danke
2020, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: rak debelega črevesa, rak danke, bolniki, zdravljenje
Published in DiRROS: 18.03.2022; Views: 737; Downloads: 396
.pdf Full text (1,30 MB)
This document has many files! More...

8.
9.
10.
Search done in 0.37 sec.
Back to top